APEX1 and cancer: Our laboratory has been developing specific inhibitors of the redox activity of Ref‐1 and has used APX3330, as well as second‐generation compounds APX2009 and APX2014, in clinical and preclinical studies in cancer as well as ocular neovascular diseases.7, 8, 9